Question

Difficulty: HardPharmacologic Interventions

An internal medicine team is evaluating a 67-year-old female who was directly admitted to the hospital with a 24-hour history of high fever, profound weakness, and new-onset gingival bleeding. Her past medical history is notable for seropositive rheumatoid arthritis, essential hypertension, and type 2 diabetes mellitus. Her home medications include weekly oral methotrexate, daily folic acid, lisinopril, and metformin. Review of her recent outpatient records reveals a visit to an urgent care clinic three days prior for dysuria, during which she was prescribed a 7-day course of trimethoprim-sulfamethoxazole.

Upon evaluation, her temperature is 38.2 °C (100.8 °F), blood pressure is 110/70 mmHg, and heart rate is 105/min. Physical examination demonstrates pale conjunctivae and scattered non-blanching petechiae across her lower extremities.

Initial laboratory studies show:

TestResult
Hemoglobin8.4 g/dL
Mean corpuscular volume108 fL
Leukocyte count1,500/mm³
Absolute neutrophil count400/mm³
Platelet count32,000/mm³
Creatinine1.6 mg/dL (baseline 0.9 mg/dL)

Blood and urine cultures have been obtained. Which of the following pharmacologic interventions are immediately indicated for this patient? (Select all that apply)

  1. Discontinue trimethoprim-sulfamethoxazoleAnswer
  2. Administer intravenous leucovorinAnswer
  3. Initiate intravenous cefepimeAnswer
  4. D
    Administer high-dose folic acid
  5. E
    Initiate oral ciprofloxacin

Answer

The correct interventions are to discontinue trimethoprim-sulfamethoxazole, administer intravenous leucovorin, and initiate intravenous cefepime.
The patient is experiencing acute methotrexate toxicity, resulting in severe pancytopenia and acute kidney injury. The correct interventions address both the root cause and the life-threatening complications.

Trimethoprim-sulfamethoxazole must be discontinued as it is the precipitating agent. It interacts with methotrexate by competing for renal tubular secretion and synergistically inhibiting folate synthesis, leading to profound bone marrow suppression.

Intravenous leucovorin (folinic acid) must be administered as it provides a source of active reduced folate that bypasses the inhibited dihydrofolate reductase enzyme, effectively rescuing the bone marrow.

Intravenous cefepime must be initiated because the patient has high-risk febrile neutropenia. With an ANC of 400/mm³ and fever in the setting of acute kidney injury, she requires immediate empiric broad-spectrum intravenous antibiotics with antipseudomonal activity.

Step-by-Step Solution

1
Identify the primary pathophysiology and the precipitating event.
The patient is experiencing severe pancytopenia and acute kidney injury due to acute methotrexate toxicity. This was triggered by the recent addition of trimethoprim-sulfamethoxazole.
Both trimethoprim and methotrexate inhibit folate metabolism. Additionally, sulfamethoxazole competes with methotrexate for renal tubular secretion, leading to toxic methotrexate accumulation.
2
Determine the immediate antidotal and corrective pharmacologic management for the toxicity.
Discontinue trimethoprim-sulfamethoxazole and administer intravenous leucovorin (folinic acid).
The offending interacting drug must be stopped. Because methotrexate blocks dihydrofolate reductase (DHFR), standard folic acid cannot be activated. Leucovorin is a reduced folate that bypasses DHFR and rescues normal cells.
3
Address the life-threatening infectious complication of the toxicity.
Initiate an intravenous antipseudomonal beta-lactam, such as cefepime.
The patient presents with high-risk febrile neutropenia (ANC of 400/mm³, fever, and end-organ dysfunction via AKI), which mandates immediate broad-spectrum empiric IV antibiotic coverage to prevent rapid progression to septic shock.

Key Concept

Acute methotrexate toxicity can be precipitated by trimethoprim-sulfamethoxazole, requiring immediate discontinuation of the interacting drug, rescue with leucovorin (which bypasses dihydrofolate reductase), and management of high-risk febrile neutropenia with IV antipseudomonal antibiotics.
Estimated Time:2m 0s
Rate this question